CRISPR-Cas12a-Based Detection of SARS-CoV-2 Harboring the E484K Mutation

María-Carmen Marqués, Raúl Ruiz, Roser Montagud-Martínez, Rosa Márquez-Costa, Sandra Albert, Pilar Domingo-Calap, and Guillermo Rodrigo*

Cite This: ACS Synth. Biol. 2021, 10, 3595−3599

ABSTRACT: The novel respiratory virus SARS-CoV-2 is rapidly evolving across the world with the potential of increasing its transmission and the induced disease. Here, we applied the CRISPR-Cas12a system to detect, without the need of sequencing, SARS-CoV-2 genomes harboring the E484K mutation, first identified in the Beta variant and catalogued as an escape mutation. The E484K mutation creates a canonical protospacer adjacent motif for Cas12a recognition in the resulting DNA amplicon, which was exploited to obtain a differential readout. We analyzed a series of fecal samples from hospitalized patients in Valencia (Spain), finding one infection with SARS-CoV-2 harboring the E484K mutation, which was then confirmed by sequencing. Overall, these results suggest that CRISPR diagnostics can be a useful tool in epidemiology to monitor the spread of escape mutations.

KEYWORDS: CRISPR diagnostics, epidemiological surveillance, virus evolution

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the coronavirus disease 2019 (COVID-19) pandemic, which has highlighted the challenges in diagnostics of viral infections, especially when a fast, massive, and reliable intervention is required to reduce the transmission. An additional problem is the emergence with time of novel SARS-CoV-2 variants that harbor specific mutations with the potential of increasing transmission of the virus and the induced disease, thereby posing concerns about the mitigation of the pandemic. In this regard, sequencing approaches are being applied worldwide to monitor the spread of the virus. However, this is a time-consuming and expensive approach that needs to be complemented with shallower and simpler techniques to maximize population testing.

In recent years, clustered regularly interspaced short palindromic repeats (CRISPR) systems have been repurposed for diagnostic applications thanks to the nonspecific collateral catalytic activity of the Cas proteins upon the specific RNA-guided targeting of the nucleic acid of interest. Owing to the exquisite sequence specificity of these systems, they can even be exploited to discriminate mutants. One mutation in SARS-CoV-2 that has gained attention is E484K, a substitution of a glutamic acid by a lysine in the receptor-binding domain of the spike protein (at the position 484 of the protein). This mutation was first identified in the Beta variant of concern (emerged in South Africa), but later it was also identified in the Gamma variant (emerged in Brazil) and in an evolved version of the Alpha variant (emerged in UK), which represent independent lineages (Figure 1A). The E484K mutation is an innovation that seems to be associated with an increased transmissibility and also with an escape from neutralizing antibodies.

In this work, we applied the CRISPR-Cas12a system, in combination with reverse transcription polymerase chain reaction (RT-PCR), to identify infections caused by variants that harbor the E484K mutation without the need of sequencing. Notably, the CRISPR-Cas12a system was already applied to detect SARS-CoV-2 in clinical samples. In the current context in which several variants of concern are emerging and causing outbreaks, enlarging its applicability to the epidemiological surveillance of key mutations seems relevant.

RESULTS AND DISCUSSION

At the nucleotide level, the E484K mutation is implemented as a substitution of a guanine by an adenine. As a result, three consecutive adenines appear in the SARS-CoV-2 genome in...
that location of the S gene (coding for the spike protein). Therefore, if a viral genome amplification process is performed, from RNA to double stranded DNA (dsDNA), a canonical protoscaler adjacent motif (PAM) sequence for Cas12a recognition is generated in the resulting amplicon if the virus harbors the E484K mutation (i.e., TTCA originally and TTTA upon mutation, in the antisense strand). We exploited this fact to develop a CRISPR-Cas12a-based system to discriminate viral genomes with this mutation. We designed a CRISPR RNA (crRNA) to target the region that immediately follows this potential PAM sequence in the sense strand of the resulting amplicon (Figure 1B). A small, fluorogenic single stranded DNA (ssDNA) molecule was used as a reporter.

We characterized the activity of the designed crRNA using different synthetic dsDNA molecules as targets. Interestingly, this crRNA allowed discriminating sequences with the E484K mutation, as the fluorescence readout significantly increased as a result of the presence of the canonical PAM sequence (Figure 1C). Yet, this crRNA also allowed detecting the original viral sequence with substantial efficiency with respect to a random sequence. Arguably, Cas12a can recognize to some extent degenerated PAM sequences, especially when pyrimidines are exchanged at one position, as it is the case of TTCA. Consequently, the designed crRNA has two potential uses, one to detect the presence of SARS-CoV-2 in the sample and another to inform about if it harbors the E484K mutation.
If required, it would be possible to use a Cas12a ortholog with stringent PAM recognition ability to only produce a significant fluorescence readout in the case of the mutant virus.9

Moreover, we characterized the system for different concentrations of the dsDNA molecule, finding consistent performance (i.e., the fold change in fluorescence was almost maintained, Figure 1D). This suggested that the discrimination of the mutant can be achieved irrespective of the efficiency of the viral genome amplification process, which is important for robust diagnostics in point-of-care applications. A kinetic characterization also showed a greater rate of fluorescence increase with time in the case of a sequence with the E484K mutation and that the CRISPR-Cas12a-based detection can be done in just 15 min (Figure 1E). The collateral cleavage rate of the ssDNA molecule roughly duplicated as a result of the presence of the canonical PAM sequence, in agreement with the end-point results presented before and suggesting double amount of active CRISPR-Cas12a-dsDNA complex in the reaction. In addition, we were able to increase the activity of the nuclease using manganese instead of magnesium in the reaction (Figure S1).10

Next, we applied the CRISPR-Cas12a system to analyze patient samples. We focused on fecal samples obtained from 10 hospitalized patients due to COVID-19 in Valencia (Spain) in May–June 2021. The analysis of feces is interesting because it can reveal a prolonged persistence of the virus in the patient, atop of a noninvasive sample collection. The patients were diagnosed by quantitative RT-PCR (RT-qPCR) as positive in SARS-CoV-2 variant with the E484K mutation, while a guanine was always found in the adenine was revealed at the corresponding position (leading to a significant PAM recognition ability to only produce a signiﬁcant fluorescence readout in the case of the mutant virus).9 Considering three additional mutations that have appeared in the S gene (Figure S3), we designed suitable crRNAs to run CRISPR-Cas12a reactions with synthetically generated dsDNA amplicons, finding possible the discrimination of the mutated sequences (Figure S4).

Previous work using CRISPR-Cas systems to detect specific point mutations in SARS-CoV-2 relied on the specificity generated by the crRNA, either with Cas12a or Cas13a.13 These methods were used to detect the D614G mutation, which arose in the first months of the pandemic and has become dominant worldwide as a consequence of providing higher infectivity to the virus.16 However, the PAM-based detection represents an original approach in which the task for sequence discrimination is displaced from the crRNA to the nuclease. Accordingly, we do not need to deal with the potential tolerance to mismatches between the crRNA and the target of these systems, thereby leading to a more straightforward design process and experimental testing. Overall, CRISPR-Cas systems seem ready to be deployed in the field to complement current diagnostic procedures and, in particular, to contribute to the epidemiological surveillance of specific escape mutations in real time during a pandemic.

### METHODS

**Patient Samples.** Fecal samples corresponding to 10 infected patients with SARS-CoV-2 (RT-qPCR diagnostics from nasopharyngeal swabs) were obtained from the Hospital Universitario y Politécnico La Fe de Valencia (Spain). The ethics committee of the Hospital Universitario y Politécnico La Fe approved this study (registration number 2020-301-1).

**RNA Extraction.** Fecal samples were resuspended in 5 mL Dulbecco’s modified Eagle’s medium (DMEM). Samples were then centrifuged twice at 3220g for 10 min at 4 °C to recover viruses in the supernatants. Supernatants were filtered through a 0.45 μm pore. RNA extraction was performed with the NucleoSpin RNA virus kit (Macherey-Nagel) following the manufacturer’s instructions.

**Virus Detection by RT-qPCR.** The TaqPath 1-step RT-qPCR master mix, CG (Applied) was used with the Centers for Disease Control and Prevention (CDC) N1 primers to amplify the SARS-CoV-2 N gene (kit provided by IDT). In a microplate (Applied), 2 μL of RNA sample were mixed with 500 nM of primers, 125 nM of probe, and the RT-qPCR mix for a total volume of 10 μL. The microplate was placed in a real-time PCR system (QuantStudio 3, Applied) with the following protocol: 50 °C for 15 min for RT, then 45 cycles of 95 °C for 3 s for denaturation and 60 °C for 30 s for annealing and extension. Samples with cycle threshold (CТ) values lower than 40 were considered as positive for SARS-CoV-2.17

**Virus Amplification by RT-PCR.** A nested PCR approach was followed to enhance the specificity and increase the yield. First, RT reactions were performed using 400 ng of total RNA (previously denatured at 65 °C for 5 min) with 500 nM of primary reverse primer to amplify the S gene, 1 nM dNTPs (NZYTech), 10 U/μL RevertAid (Thermo), and 1 U/μL RNase inhibitor (Thermo). This reaction was incubated at 42 °C for 60 min, followed by an inactivation step. Then, 2 μL of product were used as the template for the first PCR with 400 nM of the primary forward and reverse primers to amplify the S gene, 200 μM dNTPs, and 0.05 U/μL Phusion high-fidelity DNA polymerase (Thermo). Reactions were incubated in a thermocycler (Eppendorf) with the following protocol: 40 cycles of 98 °C for 10 s for denaturation, 66 °C for 10 s for
CRISPR-Cas Elements. The crRNA was generated by in vitro transcription with the TranscriptAid T7 high yield transcription kit (Thermo). Then, 2 μL of the first PCR were used for the second PCR. The reaction conditions were the same as before, unless in this case the secondary forward and reverse primers were used, the annealing was done at 62 °C, and 45 cycles were applied.

**Virus Detection by CRISPR-Cas12a.** In a microplate (Applied), 2 μL of amplified dsDNA were mixed with 17 μL of CRISPR-Cas12a ribonuclease protein (previously formed) and 1 μL of ssDNA probe (chemically synthesized by IDT, at 500 nM). The ssDNA probe was labeled with fluorescein in the 5’ end and with a dark quencher in the 3’ end. The microplate was placed in a real-time PCR system (QuantStudio 3, Applied), incubating for 1 h at 37 °C and measuring green fluorescence each 5 min. Excitation was at 470 nm and emission at 520 nm. Represented fluorescence values correspond to absolute signals minus the background signal obtained in absence of dsDNA.

**Virus Sequencing.** Amplified dsDNA molecules from the SARS-CoV-2 S gene were sent to Eurofins Genomics for Sanger sequencing with the primary forward primer.

### ASSOCIATED CONTENT

#### Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acssynbio.1c00323.

Supporting figures and tables; Sequences of all nucleic acids used in this work provided in Table S1; Information about the RT-qPCR experiments [17] provided in Table S2 (PDF)

### AUTHOR INFORMATION

**Corresponding Author**

Guillermo Rodrigo − Institute for Integrative Systems Biology (I2SysBio), CSIC − University of Valencia, 46980 Paterna, Spain; Email: guillermo.rodrigo@csic.es

**Authors**

Maria-Carmen Marqué − Institute for Integrative Systems Biology (I2SysBio), CSIC − University of Valencia, 46980 Paterna, Spain

Raúl Ruiz − Institute for Integrative Systems Biology (I2SysBio), CSIC − University of Valencia, 46980 Paterna, Spain

Roser Montagud-Martinez − Institute for Integrative Systems Biology (I2SysBio), CSIC − University of Valencia, 46980 Paterna, Spain

Rosa Márquez-Costa − Institute for Integrative Systems Biology (I2SysBio), CSIC − University of Valencia, 46980 Paterna, Spain

Sandra Albert − Institute for Integrative Systems Biology (I2SysBio), CSIC − University of Valencia, 46980 Paterna, Spain

Pilar Domingo-Calap − Institute for Integrative Systems Biology (I2SysBio), CSIC − University of Valencia, 46980 Paterna, Spain

Complete contact information is available at: https://pubs.acs.org/10.1021/acssynbio.1c00323

**Author Contributions**

GR conceived this work. MCM, RR, RMM, and RMC performed the CRISPR-Cas12a experiments and analyzed the data under the supervision of GR. SA and PDC collected the clinical samples and performed the RT-qPCR experiments. GR wrote the manuscript.

**Notes**

The authors declare no competing financial interest.

### ACKNOWLEDGMENTS

We thank M. Carmen Montaner, Javier Pemán, Miguel Salavert, and Alba Ruiz from the Hospital Universitario y Politécnico La Fe for their support in the collection of the fecal samples. This work was supported by the Fondo Supera COVID-19 from CRUE and Banco Santander (Grant COV-CRISPI, BOE-A-2020-7995, to GR), the CSIC PTI Salud Global (Grant SGL2021-03-040, to GR, and Grants 202020E292 and SGL210304, to PDC) through the European Union—NextGenerationEU, the Fondo COVID-19 from the Instituto de Salud Carlos III (Grant COV20/00210, to PDC), and the Generalitat Valenciana (Grant SEJI/2020/011, to GR). PDC was supported by the Ramón y Cajal program (RYC2019-028015-I) and RMC by a predoctoral fellowship (PRE2019-088531), both from the Spanish Ministerio de Ciencia e Innovación.

### REFERENCES

(1) Mina, M. J.; Parker, R.; Larremore, D. B. Rethinking COVID-19 test sensitivity M A strategy for containment. N. Engl. J. Med. 2020, 383, No. e120.

(2) Wu, A.; Wang, L.; Zhou, H. Y.; Ji, C. Y.; Xia, S. Z.; et al. One year of SARS-CoV-2 evolution. Cell Host Microbe 2021, 29, 503–507.

(3) du Plessis, L.; McCrone, J. T.; Zarebski, A. E.; Hill, V.; Ruis, C.; et al. Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK. Science 2021, 371, 708–712.

(4) Li, Y.; Li, S.; Wang, J.; Liu, G. CRISPR/Cas systems towards next-generation biosensing. Trends Biotechnol. 2019, 37, 730–743.

(5) Gootenberg, J. S.; Abudayeh, O. O.; Lee, J. W.; Gootenberg, J. S.; Abudayeh, O. O.; Lee, J. W.; Esletzbichler, P.; Dy, A. J.; et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science 2017, 356, 438–442.

(6) Tegally, H.; Wilkinson, E.; Giovanetti, M.; Irnandez, A.; Fonseca, V.; et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 2021, 592, 438–443.

(7) Greaney, A. J.; Starr, T. N.; Gilchuk, P.; Zost, S. J.; Binstein, R.; et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 2021, 29, 44–57.

(8) Broughton, J. P.; Deng, X.; Yu, G.; Fasching, C. L.; Servellita, V.; et al. CRISPR-Cas12-based detection of SARS-CoV-2. Nat. Biotechnol. 2020, 38, 870–874.
(9) Chen, P.; Zhou, J.; Wan, Y.; Liu, H.; Li, Y.; et al. A Cas12a ortholog with stringent PAM recognition followed by low off-target editing rates for genome editing. *Genome Biol.* 2020, 21, 78.

(10) Ma, P.; Meng, Q.; Sun, B.; Zhao, B.; Dang, L.; et al. McCas12a, a highly sensitive and specific system for COVID-19 detection. *Adv. Sci.* 2020, 7, 2001300.

(11) Sun, J.; Xiao, J.; Sun, R.; Tang, X.; Liang, C.; et al. Prolonged persistence of SARS-CoV-2 RNA in body fluids. *Emerging Infect. Dis.* 2020, 26, 1834–1838.

(12) Zhao, Y.; Chen, F.; Li, Q.; Wang, L.; Fan, C. Isothermal amplification of nucleic acids. *Chem. Rev.* 2015, 115, 12491–12545.

(13) Gao, L.; Cox, D. B. T.; Yan, W. X.; Manteiga, J. C.; Schneider, M. W.; et al. Engineered Cpf1 variants with altered PAM specificities. *Nat. Biotechnol.* 2017, 35, 789–792.

(14) Meng, Q.; Wang, X.; Wang, Y.; Dang, L.; Liu, X.; et al. Detection of the SARS-CoV-2 D614G mutation using engineered Cas12a guide RNA. *Biotechnol. J.* 2021, 16, 2100040.

(15) Wang, Y.; Zhang, Y.; Chen, J.; Wang, M.; Zhang, T.; et al. Detection of SARS-CoV-2 and its mutated variants via CRISPR-Cas13-based transcription amplification. *Anal. Chem.* 2021, 93, 3393–3402.

(16) Korber, B.; Fischer, W. M.; Gnanakaran, S.; Yoon, H.; Theiler, J.; et al. Tracking changes in SARS-CoV-2 Spike: Evidence that D614G increases infectivity of the COVID-19 virus. *Cell* 2020, 182, 812–827.

(17) Bustin, S. A.; Benes, V.; Garson, J. A.; Hellemans, J.; Huggett, J.; et al. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. *Clin. Chem.* 2009, 55, 611–622.